Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20841423 | 0.77 | BCHE (0.48) | BCHEALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL768750 | 0.76 | GABRP (0.46) | BCHEALDH1A1HSD17B10GPR3KIF11 | |
| SCHEMBL30556736 | 0.71 | METAP2 (0.38) | ALDH1A1HSD17B10KDM4EMEN1CYP1A2 | |
| SCHEMBL31619990 | 0.71 | METAP2 (0.38) | ALDH1A1HSD17B10KDM4EMEN1CYP1A2 | |
| SCHEMBL1726238 | 0.71 | IDO1 (0.49) | ALDH1A1HSD17B10GPR3KDM4ECYP1A2 | |
| SCHEMBL1323291 | 0.70 | ESR1 (0.47) | ALDH1A1HSD17B10GPR3KIF11AHR | |
| SCHEMBL2649214 | 0.70 | — | — | |
| SCHEMBL15430824 | 0.69 | GABRP (0.51) | ALDH1A1HSD17B10GPR3KIF11AHR | |
| SCHEMBL17145024 | 0.69 | BCHE (0.41) | BCHEALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL18035101 | 0.69 | ALDH1A1 (0.36) | ALDH1A1HSD17B10GPR3KIF11CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2923703-B1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO INC (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9221798-B2 | 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof | Zhejian Hisun Pharmaceutical Co., Ltd. (CN) | 2015-12-29 | — | — | US | disclosed |
| EP-2923703-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2425840-B1 | Triazine derivatives and their therapeutical applications | ABRAXIS BIOSCIENCE INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20140378488-A1 | 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2014-12-25 | — | — | US | disclosed |
| CN-103781779-A | 4-substituted- (3-substituted-1H-pyrazole-5-amino) -pyrimidine derivative with protein kinase inhibitory activity and application thereof | ZHEJIANG HISUN PHARM CO LTD | 2014-05-07 | — | — | CN | disclosed |
| US-8580786-B2 | Triazine derivatives and their therapeutical applications | NANT HOLDINGS IP, LLC (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2425840-A1 | Triazine derivatives and their therapeutical applications | Abraxis BioScience, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| WO-2005007652-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1465888-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1465635-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 2-(4-BENZYL-PIPERAZIN-1-YLMETHYL)- AND 2-(4-BENZYL-DIAZEPAN-1-YLMETHYL)-1H-BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20030229074-A1 | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues | NEUROGEN CORPORATION | 2003-12-11 | — | — | US | disclosed |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORPORATION | 2003-11-20 | — | — | US | disclosed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003059289-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060475-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 2-(4-BENZYL-PIPERAZIN-1-YLMETHYL)- AND 2-(4-BENZYL-DIAZEPAN-1-YLMETHYL)-1H-BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378488-A1 | 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF | MAP4K2, MAP4K1, MAP4K3 | BCHE 4124/4885ALDH1A1 3927/4885HSD17B10 4548/4885 |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | MCHR1, MCHR2, MC1R | BCHE 1917/4885ALDH1A1 1474/4885HSD17B10 811/4885 |
| US-20030229074-A1 | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues | MCHR1, MCHR2, MC1R | BCHE 2540/4885ALDH1A1 1225/4885HSD17B10 1178/4885 |
| US-20110150763-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | BAZ2A, CAMKK2, BAZ1A | BCHE 3693/4885ALDH1A1 3429/4885HSD17B10 3668/4885 |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | BCHE 2564/4885ALDH1A1 1647/4885HSD17B10 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.